Association of opioid receptors gene OPRM1 polymorphism and phenotypic diversity of chronic pain syndrome of oncological genesis
Abstract
The authors presented an overview of literature, which reflects the results of the recent studies of associations of carrying single nucleotide polymorphisms of the OPRM1 gene for opioid receptors involved in pain perception and response to analgesic therapy. The authors emphasized the phenotypic variability of chronic pain syndrome in patients with oncopathology.
Keywords
хронический болевой синдром,
онкология,
однонуклеотидный полиморфизм (ОНП),
опиоидные рецепторы,
ген мю-опиоидного рецептора 1 типа (OPRM1),
фармакогенетика,
эффективность,
безопасность,
chronic pain syndrome,
oncology,
single nucleotide polymorphisms (SNPs),
opioid receptors,
mu-opioid receptor type 1 gene (OPRM1),
pharmacogenetics,
efficacy,
safety
About the Authors
O. P. Bobrova
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation
Russian Federation
N. A. Shnayder
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
Russian Federation
Russian Federation
S. K. Zyryanov
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
A. A. Modestov
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation
Russian Federation
References
1. Абузарова ГР. Диагностика и дифференцированная фармакотерапия хронического болевого синдрома у онкологическихбольных. ГЭОТАР-Медия, 2015.
2. Bаr KJ, Terhaar J, Boettger MK et al. Pseudohypoalgesia on the skin: a novel view on the paradox of pain perception in depression. J. Clin. Psychopharmacol. 2011; 31 (1): 103-107.doi: 10.1097/JCP.0b013e3182046797.
3. Andersen SE. Drugdispensingerrorsin a wardstocksystem. Basic Clin. Pharmacol. Toxicol. 2010; 106 (2): 100-105. doi: 10.1111/j.1742-7843.2009.00481.x.
4. McKeen MJ and Quraishi SA. Clinical review of intravenous opioids in acute care. Journal of Anesthesiology and Clinical Science.2013:1-11.doi : http://dx.doi.org/10.7243/2049-9752-2-1.
5. Арбак ДМ, Абузарова ГР, Алексеева ГС. Опиоидные анальгетики в клинической медицине xxІв.Российский журнал боли. 2014; 2:39 - 50.
6. Lennon FE, Moss J, Singleton PA. The m-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012;116: 940-945.doi:10.1097/ALN.0b013e31824b9512.
7. Bastami S. Practical and clinical use of opioids. Liu-Tryck, 2013.
8. Gretton SK and Droney J. Splice variation of the mu-opioid receptor and its effecton the action of opioids. British Journal of Pain. 2014; 8(4):133-138.doi:10.1177/2049463714547115.
9. Dietis N, Rowbotham DJ and Lambert DG. Opioid receptor subtypes: factor artifact? Br J Anaesth. 2011 Jul; 107(1):8 - 18.doi: 10.1093/bja/aer115.
10. Pasternak GW. Molecular insights into mu opioid pharmacology: from the clinic to the bench. Clin J Pain.2010 Jan;26 (10): 10:3 - 9.doi: 10.1097/AJP.0b013e3181c49d2e.
11. Neziri AY, Scaramozzino P, Andersen OK. et al. Reference values of mechanical and thermal pain tests in a pain free population. Eur. J. Pain. 2011; 15 (4): 376-383.doi: 10.1016/j.ejpain.2010.08.011.
12. Ross JR, Riley J, Quigley C.et al. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients.The Oncologist.2006;11:765 - 773.doi:10.1634/theoncologist.11-7-765.
13. Williams JT, Ingram SL, Henderson G et al. Regulation of µ-opioid receptors: desensitization, phosphorylation, internalization and tolerance. Pharmacol Rev. 2013 Jan 15; 65 (1): 223 - 54.doi: 10.1124/pr.112.005942.
14. Branford R, Droney J, Ross JR. Opioid genetics: the key to personalized pain control? Clin Genet. 2012; 82: 301-310.doi: 10.1111/j.1399-0004.2012.01923.x.
15. HuangP, ChenC, MagueSDet al. A common single nucleotide polymorphism A118G of the m-opioid receptor alters its N-glycosylation and protein stability. BiochemJ. 2012;441(1):379 - 386.doi: 10.1042/BJ20111050.
16. Yiannakopoulou E. Pharmacogenomics and Opioid Analgesics: Clinical Implications. International Journal of Genomics. 2015:1. http://dx.doi.org/10.1155/2015/368979.
17. GregoriSde, GregoriMde, Guglielmina N R. et al. Morphine metabolism transport and brain disposition. Metab Brain Dis. 2012; (27):1 - 5.doi: 10.1007/s11011-011-9274-6.
18. Knapman A, Connor M. Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human m-opioid receptor (OPRM1). Br J Pharmacol. 2015;(172): 349 - 363.doi: 10.1111/bph.12644.
19. Laugsand EA, Skorpen F, Kaasa Set al. Genetic and non-genetic factors associated with constipation in cancer patients receiving opioids. Clinical and Translational Gastroenterology. 2015: 1 - 6.doi: 10.1038/ctg.2015.19
20. Klepstad P, Fladvad T, Skorpen Fet al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011; 152(5): 1139 - 1145.doi: 10.1016/j.pain.2011.01.040.
21. Argoff CE. Clinical Implications of opioid pharmacogenetics. Clinical journal of pain. 2010January ;26 (10) : 16 - 20.doi: 10.1097/AJP.0b013e3181c49e11.
22. Женило ВМ, Махари ОА. Влияние полиморфизма гена oprm1 118a/g на перцепцию боли и фармакодинамику наркотических аналгетиков. Общая реаниматология. 2014 x; (1): 58-63.
23. Sato H, Droney J, Ross J, Olesen AE, Staahl C, Andresen T, Branford R, Riley J, Arendt-Nielsen L, Drewes AM. Gender, Variation in opiod receptor genes and sensitivity to experimental pain. Molecular Pain. 2013. 9:20.doi: 10.1186/1744-8069-9-20
24. Jones JD, Luba RR, Vogelman JL et al. Searching for Evidence of Genetic Mediation of Opioid Withdrawal by opioid receptor gene polymorphisms. The American Journal on Addictions. 2016; (25): 41- 48.doi: 10.1111/ajad.12316.
25. Knapman A, Santiago M, Connor M. A6V polymorphism of the human -opioid receptor decreases signalling of morphine and endogenous opioids in vitro. British Journal of Pharmacology. 2015;(172): 2258 - 2272.doi: 10.1111/bph.13047.
26. Fenech AG and Grech G. Pharmacogenetics: the science of predictive clinical pharmacology. Xjenza Online - Journal of the Malta Chamber of Scientists.2013:15-32.doi: http://dx.medra.org/10.7423/xjenza.2014.1.03.
27. Janicki PK. Pharmacogenomics of Pain Management. American Academy of Pain Medicine, 2013.
28. Muralidharan A, Smith MT. Painanalgesia and genetics. J Pharm Pharmacol. 2011 Nov;63(11):1387 - 400.doi: 10.1111/j.2042-7158.2011.01340.x.
29. Droney JM., Gretton SK, Sato H. et al. Analgesia and central side-effects: two separate dimensions of morphine response. Br J Clin Pharmacol. 2013 May; 75(5): 1340-1350. doi:10.1111/bcp.12008.
30. Lоtsch J, GeisslingerG.Pharmacogenetics of new analgesics.British Journal of Pharmacology. 2011;(163):447 - 460.doi: 10.1111/j.1476-5381.2010.01074.x.
31. Zhang W, Chang YZ, Kan QC. et al. Association of human l-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecologicalpatients. Anaesthesia.2010;(65):130 - 135. doi:10.1111/j.1365-2044.2009.06193.x.
32. Lu Z, Xu J, Xu M. et al. Morphine regulates expression of m-opioid receptor MOR-1aan intron-retention carboxyl terminal splice variant of the m-opioid receptor (OPRM1) gene via miR - 103/miR-107s. Pan Mol Pharmacol. 2014 February; (85) :368 - 380.doi:10.1124/mol.113.089292.
33. Kasai S, Ikeda K. Pharmacogenomics of the human µ-opioid receptor. Pharmacogenomics. 2011; (12): 1305-1320.doi:10.1124/mol.113.089292.
34. Janicki PK. Pharmacogenomics of pain management.American Academy of Pain Medicine. 2013: 23 - 33.doi 10.1007/978-1-4614-1560-2_2.
35. Yao P, Ding Y-Y, Wang Z-Bet al. Effect of gene polymorphism of COMT and OPRM1 on the preoperative pain sensitivity in patients with cancer. Int J Clin Exp Med 2015;8(6):10036-10039.
36. Al-Hasani R, Bruchas MR. Molecular Mechanisms of opioid receptor-dependent Signaling and Behavior. Anesthesiology. 2011(115): 1363. doi: 10.1097/ALN.0b013e318238bba6.
37. Nielsen LM, Olesen AE, Sato H, Christrup LL, Drewes AM. Association between gene polymorphisms and pain sensitivity assessed in a multi-modal multi-tissue human experimental model - an explorative study.BasicClinPharmacolToxicol. 2016 Oct;119(4):360-6. doi: 10.1111/bcpt.12601.
38. Beer B, Erb R, Pavlic M, Ulmer H, Giacomuzzi S, Riemer Y, Oberacher H. Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study.PLoS One. 2013 Sep 25;8(9):e75359. doi: 10.1371/journal.pone.0075359.
Review
For citations:
Bobrova O.P., Shnayder N.A., Zyryanov S.K., Modestov A.A. Association of opioid receptors gene OPRM1 polymorphism and phenotypic diversity of chronic pain syndrome of oncological genesis. Medical Genetics. 2017;16(6):3-8. (In Russ.)
Views:
887
Email this article 